308430.Kq
308430.KQ is a pharmaceutical company that develops and commercializes prescription drugs, primarily generating revenue through the sale of its therapeutic products in domestic and international markets.
Business. 308430.KQ is a pharmaceutical company that develops and commercializes prescription drugs, primarily generating revenue through the sale of its therapeutic products in domestic and international markets.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
308430.KQ is a pharmaceutical company that develops and commercializes prescription drugs, primarily generating revenue through the sale of its therapeutic products in domestic and international markets.
The company's capital structure is characterized by a debt-to-equity ratio of 0.37, indicating a relatively conservative leverage position compared to the industry median of 0.52. However, its liquidity position is weak, with negative free cash flow of -8.37 billion KRW and operating cash flow of -5.55 billion KRW, which is below the industry median of -1.2 billion KRW. The current ratio of 11.1 suggests strong short-term liquidity, but this is largely driven by high total assets rather than positive operating cash flow.
Profitability metrics are severely negative, with a return on equity of -33.24% and return on assets of -21.52%, both well below the industry median of 12.4% and 8.7%, respectively. The company reported a net loss of 7.57 billion KRW and an operating loss of 8.24 billion KRW, which is a significant deviation from the industry's average net profit margin of 18.3%. These figures indicate a company in distress, with no clear path to profitability in the near term.
Geographically, the company's revenue is concentrated in its domestic market, with no disclosed international segments. Segment-wise, the company operates as a single business unit, which increases its exposure to market-specific risks. The lack of diversification in both geography and product lines amplifies the impact of any adverse regulatory or economic developments.
The company's growth trajectory is negative, with no disclosed revenue growth in the current fiscal year. The outlook for the next fiscal year is also uncertain, with no clear drivers of revenue expansion. The company's capital expenditure of -1.68 billion KRW suggests a reduction in investment, which may indicate a strategic shift or financial constraints. The absence of positive growth signals is a red flag for investors.
Risk factors include a high probability of liquidity stress, as the company's operating cash flow is insufficient to cover its debt obligations. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the net cash position is negative after subtracting total debt. The company has not disclosed any recent equity issuances or dilution events, but the negative free cash flow suggests a potential need for external financing in the near term.
Recent events include a significant operating loss and a net loss, which were disclosed in the latest financial filing. The company has not issued any press releases or earnings transcripts that indicate a turnaround strategy or new product launches. The absence of positive news or strategic initiatives further reinforces the perception of a company in decline.
- The company is operating at a significant loss, with a return on equity of -33.24% and a return on assets of -21.52%.
- Liquidity is strong on paper due to a current ratio of 11.1, but this is driven by high total assets rather than positive cash flow.
- The company's capital structure is conservative, with a debt-to-equity ratio of 0.37, but its negative free cash flow of -8.37 billion KRW raises concerns about long-term sustainability.
- The company lacks diversification in both geography and product lines, increasing its exposure to market-specific risks.
- No recent strategic initiatives or positive financial developments have been disclosed, suggesting a lack of direction or momentum.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 308430.KQ Market data — financials · 2026-05-26